BACKGROUND: Paclitaxel and docetaxel are considered fundamental drugs in the treatment of breast cancer. OBJECTIVES: To review the current role of taxanes in the treatment breast cancer, with emphasis on data from randomized trials comparing the two taxanes. METHODS: We have reviewed the available evidence in the literature to gauge the results of therapy of early and advanced breast cancer with taxanes. RESULTS: Clinically benefits were first shown in metastatic setting. More recently, benefits have also been seen in the therapy of early-stage disease. It seems reasonable to consider either drug as standard treatment for node-positive early stage or metastatic breast cancer. Future studies should explore the optimal way of combining taxanes with novel biological and cytotoxic drugs. CONCLUSION: Based on existing evidence, clinicians should choose a taxane-based regimen for their patients, according to clinical activity, toxicity profile, pharmacokinetics, and a dosing schedule that best meets the therapeutic needs and convenience.
BACKGROUND:Paclitaxel and docetaxel are considered fundamental drugs in the treatment of breast cancer. OBJECTIVES: To review the current role of taxanes in the treatment breast cancer, with emphasis on data from randomized trials comparing the two taxanes. METHODS: We have reviewed the available evidence in the literature to gauge the results of therapy of early and advanced breast cancer with taxanes. RESULTS: Clinically benefits were first shown in metastatic setting. More recently, benefits have also been seen in the therapy of early-stage disease. It seems reasonable to consider either drug as standard treatment for node-positive early stage or metastatic breast cancer. Future studies should explore the optimal way of combining taxanes with novel biological and cytotoxic drugs. CONCLUSION: Based on existing evidence, clinicians should choose a taxane-based regimen for their patients, according to clinical activity, toxicity profile, pharmacokinetics, and a dosing schedule that best meets the therapeutic needs and convenience.
Authors: Jielu Zhao; Susan Bane; James P Snyder; Haipeng Hu; Kamalika Mukherjee; Carla Slebodnick; David G I Kingston Journal: Bioorg Med Chem Date: 2011-10-13 Impact factor: 3.641
Authors: Kurt R Brunden; John Q Trojanowski; Amos B Smith; Virginia M-Y Lee; Carlo Ballatore Journal: Bioorg Med Chem Date: 2013-12-30 Impact factor: 3.641
Authors: Erin B Dickerson; William H Blackburn; Michael H Smith; Laura B Kapa; L Andrew Lyon; John F McDonald Journal: BMC Cancer Date: 2010-01-11 Impact factor: 4.430